The first real mouse model of prostate cancer was the TRAMP model developed using a probasin promoter and the SV40 Tag (Tumor antigen) which inhibits both p53 and Rb expression. The Tag proved to produce neuroendocrine tumors in almost all targeted organs. Here is an example of a neuroendocrine tumor (NET) in the mouse prostate.
As with the human NET prostate cancers, the mouse TRAMP tumors stain with anti-Synaptophysin.
These tumors have a number of interesting molecular networks that are also found in the human NET such as the HIF1a network.
Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, Ward JM, Cardiff RD. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res. 2004 Mar 15;64(6):2270-305. Review. PubMed PMID: 15026373.
Chiaverotti T, Couto SS, Donjacour A, Mao JH, Nagase H, Cardiff RD, Cunha GR, Balmain A. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol. 2008 Jan;172(1):236-46. Epub 2007 Dec 21. PubMed PMID: 18156212; PubMed Central PMCID: PMC2189611.
Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, Williams R, Krajewski S, Mercola D, Carpenter PM, Bowtell D, Ronai ZA. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell. 2010 Jul 13;18(1):23-38. PubMed PMID: 20609350; PubMed Central PMCID: PMC2919332.
Powered by Facebook Comments